| Medical and Health Sciences | Lifetime | 49 | US 27 | 100.00 |
| Economics and Finance | Lifetime | 930 | US 511 | 99.42 |
| Medical and Health Sciences | 2021-2025 | 37 | US 19 | 99.99 |
| Economics and Finance | 2021-2025 | 154 | US 12 | 99.56 |
| Psychiatry and Mental health | Lifetime | 4 | US 4 | 99.98 |
| Medical Physiology | Lifetime | 25 | US 16 | 99.97 |
| Clinical Pharmacology | Lifetime | 23 | US 10 | 99.89 |
| Clinical Neurology | Lifetime | 93 | US 40 | 99.68 |
| Econometrics and Quantitative Economics | Lifetime | 563 | US 328 | 99.46 |
| Neuroscience of Neurology | Lifetime | 123 | US 51 | 99.01 |
| Philosophy of Mind, Language and Cognitive Science | Lifetime | 99 | US 45 | 98.78 |
| Cognitive Neuroscience | Lifetime | 426 | US 220 | 99.04 |
| Clinical Psychology | Lifetime | 796 | US 497 | 98.84 |
| Computational Theory and Mathematics | Lifetime | 551 | US 218 | 97.54 |
| Complementary and Alternative Medicine | Lifetime | 448 | US 160 | 97.32 |
| Cellular and Molecular Neuroscience | Lifetime | 736 | US 377 | 96.67 |
| Communication | Lifetime | 909 | US 439 | 93.47 |
| Geriatrics and Gerontology | Lifetime | 345 | US 136 | 90.78 |
| Medicinal and Pharmaceutical Chemistry | Lifetime | 193 | US 75 | 89.60 |
| Medical Physiology | 2021-2025 | 2 | US 1 | 99.97 |
| Psychiatry and Mental health | 2021-2025 | 8 | US 4 | 99.91 |
| Clinical Pharmacology | 2021-2025 | 8 | US 2 | 99.41 |
| Econometrics and Quantitative Economics | 2021-2025 | 134 | US 7 | 99.54 |
| Molecular Biology | 2021-2025 | 947 | US 265 | 94.63 |
| Neuroscience of Neurology | 2021-2025 | 266 | US 94 | 83.34 |
| Cognitive Neuroscience | 2021-2025 | 946 | US 397 | 79.41 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 1 | US 1 | 99.98 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 3 | US 1 | 99.92 |
| Computational Drug Discovery Methods | Lifetime | 8 | US 6 | 99.79 |
| Alzheimer's disease research and treatments | Lifetime | 15 | US 12 | 99.97 |
| Dementia and Cognitive Impairment Research | Lifetime | 7 | US 6 | 99.98 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 26 | US 11 | 99.87 |
| Ginkgo biloba and Cashew Applications | Lifetime | 6 | US 2 | 99.56 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 95 | US 38 | 99.61 |
| Cancer therapeutics and mechanisms | Lifetime | 85 | US 56 | 99.37 |
| Neurological and metabolic disorders | Lifetime | 23 | US 10 | 99.12 |
| Bioactive Compounds and Antitumor Agents | Lifetime | 51 | US 30 | 98.99 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 65 | US 26 | 99.39 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 112 | US 42 | 99.42 |
| Schizophrenia research and treatment | Lifetime | 150 | US 71 | 99.42 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 161 | US 57 | 98.99 |
| Attention Deficit Hyperactivity Disorder | Lifetime | 151 | US 95 | 98.67 |
| Pharmaceutical Economics and Policy | Lifetime | 97 | US 53 | 98.27 |
| Healthcare Decision-Making and Restraints | Lifetime | 61 | US 33 | 98.14 |
| Psychosomatic Disorders and Their Treatments | Lifetime | 145 | US 49 | 98.69 |
| Genetic Neurodegenerative Diseases | Lifetime | 214 | US 91 | 98.67 |
| Functional Brain Connectivity Studies | Lifetime | 387 | US 187 | 99.01 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 83 | US 47 | 97.98 |
| Mental Health and Psychiatry | Lifetime | 163 | US 79 | 98.53 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 324 | US 129 | 97.33 |
| Frailty in Older Adults | Lifetime | 357 | US 134 | 97.28 |
| Cancer Treatment and Pharmacology | Lifetime | 933 | US 448 | 97.54 |
| Epilepsy research and treatment | Lifetime | 826 | US 341 | 96.88 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 769 | US 285 | 96.72 |
| Tryptophan and brain disorders | Lifetime | 721 | US 295 | 96.83 |
| Health, Environment, Cognitive Aging | Lifetime | 294 | US 145 | 95.93 |
| Medicinal Plants and Neuroprotection | Lifetime | 296 | US 19 | 94.25 |
| Obsessive-Compulsive Spectrum Disorders | Lifetime | 433 | US 206 | 96.21 |
| Memory and Neural Mechanisms | Lifetime | 874 | US 449 | 96.06 |
| Body Image and Dysmorphia Studies | Lifetime | 222 | US 94 | 95.30 |
| Statistical Methods in Clinical Trials | Lifetime | 481 | US 252 | 94.74 |
| Nuclear Receptors and Signaling | Lifetime | 442 | US 208 | 94.27 |
| Treatment of Major Depression | Lifetime | 710 | US 351 | 95.31 |
| Hallucinations in medical conditions | Lifetime | 42 | US 7 | 91.97 |
| Neutropenia and Cancer Infections | Lifetime | 998 | US 425 | 92.68 |
| Cancer-related cognitive impairment studies | Lifetime | 427 | US 238 | 91.63 |
| Prion Diseases and Protein Misfolding | Lifetime | 589 | US 202 | 92.48 |
| Neurology and Historical Studies | Lifetime | 268 | US 122 | 90.50 |
| Alcoholism and Thiamine Deficiency | Lifetime | 484 | US 221 | 90.56 |
| Family Caregiving in Mental Illness | Lifetime | 539 | US 178 | 89.44 |
| Pain Management and Placebo Effect | Lifetime | 911 | US 392 | 89.52 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 288 | US 97 | 88.33 |
| Intellectual Capital and Performance Analysis | Lifetime | 557 | US 91 | 86.92 |
| Spatial Neglect and Hemispheric Dysfunction | Lifetime | 564 | US 165 | 87.22 |
| Cerebrovascular and genetic disorders | Lifetime | 659 | US 168 | 80.60 |
| Information Systems Education and Curriculum Development | Lifetime | 621 | US 413 | 59.88 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 1 | US 1 | 99.91 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 4 | US 1 | 99.82 |
| Alzheimer's disease research and treatments | 2021-2025 | 5 | US 2 | 99.95 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 8 | US 5 | 99.93 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 49 | US 8 | 98.87 |
| Computational Drug Discovery Methods | 2021-2025 | 87 | US 11 | 98.31 |
| Tryptophan and brain disorders | 2021-2025 | 104 | US 23 | 96.98 |
| Bioinformatics and Genomic Networks | 2021-2025 | 134 | US 35 | 93.55 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 475 | US 141 | 92.88 |
| Cancer-related cognitive impairment studies | 2021-2025 | 80 | US 39 | 92.71 |
| Schizophrenia research and treatment | 2021-2025 | 253 | US 49 | 95.17 |
| Pharmaceutical Economics and Policy | 2021-2025 | 145 | US 57 | 91.42 |
| Healthcare Decision-Making and Restraints | 2021-2025 | 86 | US 22 | 89.45 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 147 | US 21 | 87.52 |
| Psychiatric care and mental health services | 2021-2025 | 158 | US 13 | 81.19 |
| Nuclear Receptors and Signaling | 2021-2025 | 154 | US 27 | 80.48 |
| Mental Health and Psychiatry | 2021-2025 | 345 | US 79 | 83.07 |
| Attention Deficit Hyperactivity Disorder | 2021-2025 | 880 | US 264 | 78.73 |
| Health, Environment, Cognitive Aging | 2021-2025 | 949 | US 401 | 76.92 |
| Pharmaceutical studies and practices | 2021-2025 | 901 | US 277 | 74.42 |
| Biomedical Ethics and Regulation | 2021-2025 | 374 | US 157 | 73.38 |
| Prion Diseases and Protein Misfolding | 2021-2025 | 504 | US 148 | 63.70 |
| Phosphodiesterase function and regulation | 2021-2025 | 537 | US 120 | 33.71 |
| Cognitive Functions and Memory | 2021-2025 | 747 | US 275 | 32.49 |